BDNF and myeloid sarcoma: TRE also has been shown to improve factors that are associated with the onset and progression of MS, such as inflammation, poor immune function, and low levels of neuroprotective agents, including brain-derived neurotropic factor (BDNF), which have all been associated with the onset and progression of MS (14, 15, 18, 19).